ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$5.45 USD
-0.15 (-2.68%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $5.45 0.00 (0.00%) 7:58 PM ET
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALXO 5.45 -0.15(-2.68%)
Will ALXO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALXO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALXO
Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe
ALXO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates
Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
Other News for ALXO
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
Insider Buying: CFO Peter Garcia Acquires Shares of ALX Oncology Holdings Inc (ALXO)
Buy Rating Affirmed for ALX Oncology Amid Promising Evorpacept Combination Therapy Results
Buy Rating Affirmed for ALX Oncology Holdings on Strong Clinical Data and Solid Financial Valuation
Wall Street Analysts Are Bullish on Top Healthcare Picks